STOCK TITAN
  1. Home
  2. News
  3. IBIO

iBio, Inc. - IBIO STOCK NEWS

Welcome to our dedicated page for iBio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on iBio stock.

iBio, Inc. (symbol: IBIO) is a specialized contract development and manufacturing organization (CDMO) that facilitates the journey from early product selection to market launch. Situated within the healthcare sector, iBio is renowned for its plant-based protein expression technologies, which are pivotal in developing vaccines, therapeutic proteins, and biopharmaceutical products.

The company operates through two primary segments: Biopharmaceuticals and Bioprocessing. iBio's Biopharmaceuticals segment focuses on the development and commercialization of product candidates aimed at addressing critical health issues such as fibrotic diseases, cancers, and infectious diseases. The Bioprocessing segment, meanwhile, involves comprehensive manufacturing and regulatory support services offered through iBio CDMO.

iBio's technology platform and state-of-the-art facilities are designed to expedite development processes, providing significant time and cost advantages over traditional approaches. The company boasts a team of skilled protein scientists, microbiologists, manufacturing experts, and regulatory professionals committed to delivering seamless scale-up from preclinical to commercial production.

Recent achievements include advancements in biotherapeutics and diagnostic products, showcasing iBio's capability to innovate and respond to global health challenges effectively. The company also maintains strategic partnerships that bolster its research and development efforts, ensuring consistent progress in the healthcare landscape.

With its focus on rapid manufacturing support and regulatory compliance, iBio stands out as a reliable partner for clients seeking efficient pathways to clinical and commercial success.

News

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Rhea-AI Summary
iBio, Inc. (IBIO) announces a strategic asset purchase agreement with Otsuka Pharmaceutical Co., Ltd., involving an upfront payment of $1 million and potential future milestone payments of up to $52.5 million. The deal focuses on iBio's early-stage PD-1 agonist program, enhancing its immuno-oncology pipeline. PD-1 agonists play a crucial role in immune system modulation, offering promising therapeutic potential for autoimmune diseases. The transaction aims to provide iBio with significant non-dilutive capital, validate its technology stack, and enable a focused approach on immuno-oncology and AI-based drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
News

iBio Announces Participation in 23rd Annual PepTalk Conference

Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) announced that its VP of Platform Technologies, Matt Greving, will give a presentation at the 23rd annual PepTalk Conference on enhancing bispecific T-cell engager discovery and development with machine learning. He will discuss how iBio's technology stack potentially overcomes challenges in the discovery of bispecific T-Cell Engagers for cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
News

iBio Amends and Extends Maturity of Credit Agreement

Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) extends maturity date of Credit Agreement to March 29, 2024, providing more time for planned divestiture of legacy CDMO business. The amendment with Woodforest National Bank allows financial flexibility for the sale of the biologics manufacturing facility in Texas and advancement of AI drug discovery platform and immunotherapy pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
News

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) announced a public offering of 2,250,000 shares of common stock and accompanying Series C and Series D warrants, resulting in gross proceeds of approximately $4.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
offering
-
News

iBio Announces Reverse Stock Split

Rhea-AI Summary
iBio, Inc. (IBIO) has approved a 20-to-1 reverse split of its common stock, effective on November 29, 2023. The reverse stock split will result in every 20 shares being combined into one share, reducing the outstanding shares from 28,100,733 to 1,405,036. The split will not affect ownership percentage except for holders of fractional shares. The exercise prices of stock options, warrants, and equity incentive plans will be adjusted accordingly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.03%
Tags
none
-
News

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Rhea-AI Summary
iBio, Inc. has announced the launch of ShieldTx, an AI-powered antibody masking technology that enables targeted delivery to diseased tissue. The technology aims to overcome challenges in complex targets, safety, and developability in antibody discovery and development. iBio used ShieldTx to develop masks for its MUC16-targeted bispecific antibody candidates. The technology deactivates the antibodies until they encounter a specific enzyme in the target tissue, reducing off-tissue side effects and enhancing therapeutic safety. ShieldTx can be applied to cancer therapeutics and autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
News

iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics

Rhea-AI Summary
iBio's VP of Platform Technologies to present on enhancing T-cell engagers at the Festival of Biologics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
-
News

iBio Explains Recent Filing of Registration Statement

Rhea-AI Summary
iBio clarifies its post-effective amendment to its Form S-3 on Form S-1, maintaining the registration of common stock warrants issued and outstanding. No new securities are being registered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
News

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Rhea-AI Summary
iBio files annual report with the SEC, reporting $nil in revenues for FY 2023 compared to $1.9 million in FY 2022. Operating expenses decrease by 7% to $29.3 million. Consolidated net loss increases by $14.6 million to $65.0 million. iBio holds $4.3 million in cash and cash equivalents and $3.3 million in restricted cash. The audited financial statements contain an audit opinion regarding the Company's ability to continue as a going concern. The maturity date of the Credit Agreement is extended to December 31, 2023, providing time to close the sale of the CDMO Facility. No assurance of closing conditions being satisfied. The divestiture of iBio's manufacturing business in Texas will extend cash runway for AI drug discovery platform and immunotherapy pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

iBio Announces Amendment to Credit Agreement with Woodforest

Rhea-AI Summary
iBio extends maturity date of credit agreement to December 31, 2023, allowing time to close pending sale of CDMO facility. Sale of facility will complete divestiture of contract development and manufacturing business. Positive for stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
none

FAQ

What is the current stock price of iBio (IBIO)?

The current stock price of iBio (IBIO) is $2.48 as of December 20, 2024.

What is the market cap of iBio (IBIO)?

The market cap of iBio (IBIO) is approximately 22.2M.

What does iBio, Inc. specialize in?

iBio specializes in plant-based protein expression technologies for developing vaccines, therapeutic proteins, and biopharmaceutical products.

What are the main segments iBio operates in?

iBio operates in two main segments: Biopharmaceuticals and Bioprocessing.

What services does iBio offer?

iBio offers comprehensive development and manufacturing services, from early product selection to regulatory approval and commercial product launch.

Who comprises iBio’s team?

iBio's team includes knowledgeable protein scientists, microbiologists, and experts in manufacturing and regulatory affairs.

What are the key areas iBio's products target?

iBio's products target fibrotic diseases, cancers, and infectious diseases.

How does iBio's technology platform benefit clients?

iBio's technology platform provides significant time and cost advantages, enabling rapid development and seamless scale-up from preclinical to commercial production.

What recent achievements has iBio made?

iBio has made advancements in biotherapeutics and diagnostic products, showcasing its innovative capabilities.

What is iBio CDMO?

iBio CDMO is the division of iBio that handles bioprocessing activities, offering manufacturing and regulatory support.

Does iBio collaborate with other organizations?

Yes, iBio maintains strategic partnerships to enhance its research and development efforts.

How can I contact iBio for investor or media relations?

You can contact Stephen Kilmer for investor relations at skilmer@ibioinc.com or Susan Thomas for media relations at susan.thomas@ibioinc.com.

Stock IBIO logo
iBio, Inc.

NYSE:IBIO

IBIO Rankings

#5263 Ranked by Market Cap
N/A Ranked by Dividends

IBIO Stock Data

22.23M
9.14M
0.14%
31.49%
2.52%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK